Curing cancer is a group effort.

Collaborating with Others

We believe the ability of the IO+ platform to deliver precise doses of multiple biologic and small molecules in combination will enable fundamental, new discoveries. We welcome the opportunity to work with partners interested in deepening knowledge of nano-medicines, basic biology, and solid tumor cancers.

The ability of the IO+ platform to enhance bio-availabiliy and target therapeutics to tumors creates opportunities to develop previously impossible cancer therapies. We invite corporate partners to contact us to learn more about our confidential partnering program.

If you are interested in partnering with Cytimmune to explore how the IO+ platform might help you deliver a better clinical result for your therapeutic asset(s), or if you would like access to Cytimmune’s pipeline therapeutics to conduct studies related to the systemic administration of high dose combination therapies, please contact us.

A few of our academic collaborations and clinical partnerships are described below.

Academic and Institutional Partners

Featured
U.S. National Cancer Institute
U.S. National Cancer Institute

The US National Cancer Institute is a long-time, committed research and clinical development partner. Our collaboration efforts began under Dr. Rosenberg’s immunology Laboratory and continue today with the endocrine oncology branch of the cancer center. Dr. Steven Libutti, former a surgeon at the NCI and now the Director of the Rutgers Cancer Institute of New Jersey, conducted the company’s phase 1 clinical trial. Oncologist and surgeon, Dr. Naris Nilubol, will be managing CytImmune’s upcoming clinical studies at the NCI. Included in these studies will be efficacy assessments of CYT-6091 in combination with nab-paclitaxel (Abraxane). We anticipate these studies will begin in late 2021 or early 2022.

Tokyo University of Science
Tokyo University of Science

CytImmune recently signed an agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune diseases to investigate and confirm synergies between TNF alpha and existing immunotherapies. Additional research and development work may also be conducted in collaboration with CytImmune on our new 2nd generation immuno oncology nanomedicines. This work will be completed in the laboratory of the Dr. Kouji Matsushima, reknowned immunologist and former President of the International Cytokine Society.